Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 30, 2025
DataAggregated Company Financials
Companies567
- 7D2.6%
- 3M-7.8%
- 1Y-9.1%
- YTD-3.4%
The Biotech is pretty flat in the last 7 days, but Amgen has stood out, gaining 4.3%. Unfortunately though, the industry is down 9.6% over the past 12 months. As for the next few years, earnings are expected to grow by 24% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 30 May 2025 | US$914.8b | US$155.9b | -US$23,981,521,247.80 | 15.7x | -38.1x | 5.9x |
| Sun, 27 Apr 2025 | US$783.3b | US$119.2b | -US$31,074,126,492.82 | 19.8x | -25.2x | 6.6x |
| Tue, 25 Mar 2025 | US$827.0b | US$118.6b | -US$36,869,226,191.93 | 20.7x | -22.4x | 7x |
| Thu, 20 Feb 2025 | US$842.4b | US$116.6b | -US$36,830,915,932.52 | 17.4x | -22.9x | 7.2x |
| Sat, 18 Jan 2025 | US$943.3b | US$149.4b | -US$26,286,132,923.67 | 17.3x | -35.9x | 6.3x |
| Mon, 16 Dec 2024 | US$991.8b | US$150.0b | -US$26,493,336,471.94 | 16.6x | -37.4x | 6.6x |
| Wed, 13 Nov 2024 | US$1.1t | US$149.6b | -US$27,274,668,753.18 | 16.1x | -40.4x | 7.4x |
| Fri, 11 Oct 2024 | US$885.7b | US$113.1b | -US$35,992,841,232.34 | 20.3x | -24.6x | 7.8x |
| Sun, 08 Sep 2024 | US$873.8b | US$113.1b | -US$35,668,533,175.32 | 22.2x | -24.5x | 7.7x |
| Tue, 06 Aug 2024 | US$1.2t | US$165.8b | -US$32,345,907,600.20 | 24.9x | -37x | 7.2x |
| Thu, 04 Jul 2024 | US$1.1t | US$164.5b | -US$27,946,912,225.84 | 27.9x | -40.1x | 6.8x |
| Sat, 01 Jun 2024 | US$1.1t | US$164.6b | -US$26,677,227,566.32 | 27.4x | -41.6x | 6.7x |
| Mon, 29 Apr 2024 | US$1.1t | US$164.6b | -US$27,372,800,636.09 | 22.6x | -39.1x | 6.5x |
| Wed, 27 Mar 2024 | US$1.2t | US$164.4b | -US$23,792,606,116.02 | 21.2x | -48.8x | 7.1x |
| Fri, 23 Feb 2024 | US$1.2t | US$169.0b | -US$20,212,652,991.58 | 13.2x | -57x | 6.8x |
| Sun, 21 Jan 2024 | US$1.4t | US$204.8b | -US$22,506,538,466.00 | 18.5x | -63.3x | 7x |
| Tue, 19 Dec 2023 | US$1.4t | US$204.7b | -US$22,117,247,361.00 | 19.2x | -61x | 6.6x |
| Thu, 16 Nov 2023 | US$1.2t | US$204.7b | -US$22,143,559,902.00 | 18.4x | -55.1x | 6x |
| Sat, 14 Oct 2023 | US$1.3t | US$207.3b | -US$13,141,713,262.00 | 16.6x | -96.4x | 6.1x |
| Mon, 11 Sep 2023 | US$1.3t | US$207.5b | -US$12,633,744,533.00 | 17.4x | -101x | 6.1x |
| Wed, 09 Aug 2023 | US$1.3t | US$206.4b | -US$12,500,248,802.00 | 16.4x | -101x | 6.1x |
| Fri, 07 Jul 2023 | US$1.1t | US$186.2b | -US$16,056,868,924.00 | 13.2x | -69.5x | 6x |
| Sun, 04 Jun 2023 | US$1.1t | US$185.9b | -US$16,014,255,509.00 | 11.4x | -71.1x | 6.1x |
| Tue, 02 May 2023 | US$1.2t | US$197.0b | -US$6,677,740,450.00 | 14x | -175.7x | 6x |
| Thu, 30 Mar 2023 | US$1.1t | US$198.3b | -US$4,280,712,821.00 | 13.8x | -266.8x | 5.8x |
| Sat, 25 Feb 2023 | US$1.1t | US$200.5b | -US$3,797,679,065.00 | 14.2x | -295.4x | 5.6x |
| Mon, 23 Jan 2023 | US$1.2t | US$203.8b | US$1.8b | 14.4x | 655.9x | 5.7x |
| Wed, 21 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.6x | 704x | 5.7x |
| Fri, 18 Nov 2022 | US$1.1t | US$202.2b | US$1.2b | 14.7x | 921.2x | 5.5x |
| Sun, 16 Oct 2022 | US$1.0t | US$206.0b | US$5.4b | 15.6x | 194.3x | 5.1x |
| Tue, 13 Sep 2022 | US$1.1t | US$206.9b | US$5.9b | 15.8x | 185.7x | 5.3x |
| Thu, 11 Aug 2022 | US$1.1t | US$208.3b | US$5.7b | 16.6x | 196.3x | 5.4x |
| Sat, 09 Jul 2022 | US$1.1t | US$211.5b | US$10.8b | 17.4x | 102.3x | 5.2x |
| Mon, 06 Jun 2022 | US$1.0t | US$212.8b | US$11.3b | 16.4x | 88.7x | 4.7x |
Price to Earnings Ratio
88.7x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.8% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 1.15% | |
| Healthcare | 1.49% | |
| Biotech | 2.60% | |
| Biotech | 2.60% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| AMGN Amgen | US$283.54 | 4.3% +US$6.3b | -5.8% | PE25.7x | |
| ABBV AbbVie | US$185.62 | 1.7% +US$5.4b | 18.8% | PE78.9x | |
| GILD Gilead Sciences | US$111.11 | 4.1% +US$5.4b | 73.4% | PE23.2x | |
| VRTX Vertex Pharmaceuticals | US$447.09 | 3.0% +US$3.4b | 0.9% | PS10.3x | |
| ONC BeOne Medicines | US$246.68 | 3.3% +US$975.3m | 59.9% | PS7x |